{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T12:09:52Z","timestamp":1769083792192,"version":"3.49.0"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"vor","delay-in-days":1830,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T00:00:00Z","timestamp":1608076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015002","name":"Relypsa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015002","name":"Relypsa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>This analysis qualitatively describes the impact of hyperkalaemia (HK) and renin-angiotensin-aldosterone system inhibitor (RAASi) use on clinical outcomes in patients with heart failure (HF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Patients were included if they were \u226518 years old; had a serum potassium result between 1 January 2003 and 3 December 2018; had \u22652 separate, non-urgent care or emergency department encounters; and had an HF diagnosis. Criteria were met by 52 253 patients; 48 333 had sufficient follow-up for analysis. Patients were stratified by the presence\/absence of HK (serum potassium &amp;gt;5.0 mmol\/L) (n = 31 619 and n = 20 634, respectively) and by baseline left ventricular ejection fraction (LVEF) \u226440% or &amp;gt;40%. Compared with patients without HK (no-HK), those with HK had significantly higher rates of baseline cardiovascular risk factors, prior diagnoses, and greater RAASi use in both baseline and follow-up periods. Assessed outcomes included RAASi use, rate of 3 year major adverse cardiovascular events (MACE), and individual component rates. Between baseline and follow-up analyses, the proportion of patients on RAASi decreased by 5% in patients with HK but increased by 20% in no-HK patients. Overall, MACE and death were consistently highest in the presence of HK without RAASi treatment (63% and 62%, respectively) and lowest in no-HK but on RAASi (25% and 21%, respectively). After complete multivariable adjustment, these trends were consistent regardless of baseline LVEF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this large, real-world HF population, HK was common and linked to baseline clinical risk factors, declining use of RAASi treatment, and an increase in future MACE, regardless of baseline LVEF. Both HK and reduced RAASi use were independent predictors of future MACE.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.13164","type":"journal-article","created":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T00:57:29Z","timestamp":1608253049000},"page":"691-696","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Frequency and Clinical Impact of Hyperkalaemia Within a Large, Modern, Real-World Heart Failure Population"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3366-9857","authenticated-orcid":false,"given":"Joseph B.","family":"Muhlestein","sequence":"first","affiliation":[{"name":"Department of Cardiology, Intermountain Medical Center Heart Institute , 5121 S. Cottonwood Street, Salt Lake City, UT, 84157 ,","place":["USA"]},{"name":"Department of Cardiology, University of Utah , Salt Lake City, UT ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Kammerer","sequence":"additional","affiliation":[{"name":"Managed Care Health Outcomes, Relypsa, Inc., a Vifor Pharma Group Company , Redwood City, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tami L.","family":"Bair","sequence":"additional","affiliation":[{"name":"Bioinformatics, Intermountain Medical Center Heart Institute , Salt Lake City, UT ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirk U.","family":"Knowlton","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Intermountain Medical Center Heart Institute , 5121 S. Cottonwood Street, Salt Lake City, UT, 84157 ,","place":["USA"]},{"name":"Department of Cardiology, University of Utah , Salt Lake City, UT ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viet T.","family":"Le","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Intermountain Medical Center Heart Institute , 5121 S. Cottonwood Street, Salt Lake City, UT, 84157 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey L.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Intermountain Medical Center Heart Institute , 5121 S. Cottonwood Street, Salt Lake City, UT, 84157 ,","place":["USA"]},{"name":"Department of Cardiology, University of Utah , Salt Lake City, UT ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald L.","family":"Lapp\u00e9","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Intermountain Medical Center Heart Institute , 5121 S. Cottonwood Street, Salt Lake City, UT, 84157 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi T.","family":"May","sequence":"additional","affiliation":[{"name":"Epidemiology, Intermountain Medical Center Heart Institute , Salt Lake City, UT ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,12,16]]},"reference":[{"key":"2026012114043614500_ehf213164-bib-0001","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.amjmed.2015.05.040","article-title":"Management of hyperkalemia: an update for the internist","volume":"128","author":"Kovesdy","year":"2015","journal-title":"Am J Med"},{"key":"2026012114043614500_ehf213164-bib-0002","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/HYPERTENSIONAHA.115.04889","article-title":"New potassium binders for the treatment of hyperkalemia: current data and opportunities for the future","volume":"66","author":"Pitt","year":"2015","journal-title":"Hypertension"},{"key":"2026012114043614500_ehf213164-bib-0003","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1001\/archinternmed.2009.132","article-title":"The frequency of hyperkalemia and its significance in chronic kidney disease","volume":"169","author":"Einhorn","year":"2009","journal-title":"Arch Intern Med"},{"key":"2026012114043614500_ehf213164-bib-0004","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/ehf2.12402","article-title":"Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21 334 patients in the UK","volume":"6","author":"Linde","year":"2019","journal-title":"ESC Heart Fail"},{"key":"2026012114043614500_ehf213164-bib-0005","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1080\/03007995.2018.1433141","article-title":"The prevalence of hyperkalemia in the United States","volume":"34","author":"Betts","year":"2018","journal-title":"Curr Med Res Opin"},{"key":"2026012114043614500_ehf213164-bib-0006","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/j.jacc.2007.07.067","article-title":"Incidence and predictors of HK in patients with heart failure: an analysis of the CHARM Program","volume":"50","author":"Desai","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2026012114043614500_ehf213164-bib-0007","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jacc.2007.04.064","article-title":"Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry","volume":"50","author":"Fonarow","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2026012114043614500_ehf213164-bib-0008","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012655","article-title":"Real-world associations of renin-angiotensin-aldosterone system inhibitor dose, hyperkalemia, and adverse clinical outcomes in a cohort of patients with new-onset chronic kidney disease or heart failure in the United Kingdom [published erratum appears in J Am Heart Assoc 2019; 8:e014500]","volume":"8","author":"Linde","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2026012114043614500_ehf213164-bib-0009","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.jacc.2016.06.060","article-title":"Hyperkalemia in heart failure","volume":"68","author":"Sarwar","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026012114043614500_ehf213164-bib-0010","volume-title":"Healthcare Cost and Utilization Project (HCUP)","author":"HCUP Databases","year":"2011"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.13164","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.13164","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/8\/1\/691\/65798918\/eschf_8_1_691.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/8\/1\/691\/65798918\/eschf_8_1_691.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:05:03Z","timestamp":1769022303000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/8\/1\/691\/8369344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,16]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12,16]]},"published-print":{"date-parts":[[2021,2,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.13164","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,2]]},"published":{"date-parts":[[2020,12,16]]},"assertion":[{"value":"2020-08-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}